Key Takeaways XRAY's review concluded that retaining Wellspect offers more value than a sale.XRAY concludes that Wellspect leads in continence care with steady growth and strong cash flows.Wellspect's $2B market and pipeline back XRAY's long-term profitability strategy.Dentsply Sirona (XRAY) recently concluded that retaining the Wellspect business portfolio is likely to create more value for its stockholders compared to other strategic alternatives. CEO Dan Scavilla emphasized that, after a comprehensive st ...